A New Normal? Continued Impact of COVID19 on Alzheimer's Clinical Trials Research. (17th December 2021)

• Record Type: Journal Article
• Authors: Rhodus, Elizabeth; Gibson, Allison; Bardach, Shoshana; Abner, Erin; Jicha, Gregory
• Is Part Of: Innovation in aging. Volume 5(2021)Supplement 1
• Page Start: 136
• Page End: 136
• Publication Date: 2021-12-17
• Subjects: Aging -- Periodicals; Gerontology -- Periodicals; 612.67
• DOI: 10.1093/geroni/igab046.527
• Languages: English
• ISSNs: 2399-5300

Abstract

Abstract: The COVID-19 pandemic has led to unprecedented challenges in Alzheimer's disease and related dementias (ADRD) clinical trials research. Scientists continue to grapple with the potential and multifaceted consequences of COVID-19. This presentation will discuss strategies used at a U.S. Alzheimer's Disease Research Center to implement virtual methods to counter COVID-19's impact on safety for continued research engagement; address the disparate impact by age, race, and ethnicity for online accessibility; and plans for virtual engagement in future research. As scientists navigate lasting implications of COVID-19, future study planning, design, and management will likely be altered. Specifically, increased awareness of participant-centered approaches, inclusion of psychosocial implications, and focus on ways to meet older adults' unique needs of virtual accessibility will be needed. We must be intentional to counter COVID-19's lasting impact on ADRD clinical trials research while maintaining rigor and reproducibility to uphold and progress advances toward treatment and cures for ADRD.